Journal of Neurogastroenterology and Motility : eISSN 2093-0887 / pISSN 2093-0879

Download original image
Table. 2. Compounds Under Development That Have Been Discontinued

aAlso see lavoltidine in Table 1.

H2RAs, histamine type 2 receptor antagonist; PPIs, proton pump inhibitors; P-CABs, potassium-competitive acid blockers; TLESR, transient lower esophageal sphincter relaxation; GABAB, γ-aminobutyric acid class B; mGluR5, metabotropic glutamate receptor 5; CB, cannabinoid; CCK, cholecystokinin; 5-HT4, 5-hydroxytryptamine 4 receptor.

J Neurogastroenterol Motil 2014;20:6~16 https://doi.org/10.5056/jnm.2014.20.1.6
© J Neurogastroenterol Motil